Hicin Pharmaceutical(SZ:300584) Xin Lang Cai Jing·2025-11-05 01:43Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical has seen a stock price increase of 5.71%, reaching 59.10 CNY per share, with a total market capitalization of 7.092 billion CNY as of the report date [1] - The company, Nanjing Hainan Pharmaceutical Co., Ltd., was established on January 15, 2003, and went public on January 12, 2017. Its main business includes the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The revenue composition of the company's main business is as follows: cardiovascular drugs 87.12%, antibiotics 5.69%, active pharmaceutical ingredients and intermediates 1.68%, digestive drugs 1.50%, antiviral drugs 1.47%, others (supplements) 0.83%, immune regulators 0.80%, other categories 0.57%, and diuretics 0.34% [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, Yongying Fund has a fund that entered the top ten shareholders in the third quarter, holding 482,400 shares, which accounts for 0.59% of the circulating shares [2] - The fund, Yongying New Materials Smart Selection Mixed Initiation A (024737), was established on July 28, 2025, with a latest scale of 71.9734 million CNY and has achieved a return of 14.22% since its inception [2] Group 3 - The fund manager of Yongying New Materials Smart Selection Mixed Initiation A is Ou Zichen, who has been in the position for 3 years and 272 days. The total asset scale of the fund is 2.624 billion CNY, with the best fund return during the tenure being 85.31% and the worst being -11.01% [3]